Novo Nordisk: Zeus Trial Shows Similar Adverse Event Rates
Novo Nordisk reports similar adverse event rates in Zeus trial
Story updates
11:22:58 AM UTC
SquawkNews
NOVO NORDISK PROVIDES UPDATE ON THE ZEUS PHASE 3 TRIAL IN PEOPLE WITH ASCVD, CKD AND INFLAMMATION || ADVERSE EVENT RATES SIMILAR; HIGHER SERIOUS INFECTIONS WITH ZILTIVEKIMAB
11:24:09 AM UTC
SquawkNews
NVO -10.5% after update on zeus phase 3 trial
NVO Novo nordisk provides update on the zeus phase 3 trial in people with ascvd, ckd and inflammation Novo nordisk - adverse event rates similar; higher serious infections with ziltivekimab - Outcome of zeus will not impact Novo nordiskâeur ™s previously communicated adjusted operating profit outlook for 2026